Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Questcor Pharmaceuticals Inc    QCOR   US74835Y1010

Delayed Quote. Delayed Nasdaq - 08/14 04:00:01 pm
93.6 USD   +1.65%
02/03DJMallinckrodt Earnings Soar on Acquisitions -- 2nd Update
02/03DJMallinckrodt Earnings Soar on Acquisitions -- Update
02/03DJMallinckrodt Earnings Soar on Acquisitions
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Questcor Pharmaceuticals, Inc. : Questcor Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

01/03/2013 | 06:35am US/Eastern

ANAHEIM, Calif., Jan. 3, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 10, 2013 at 9:00 a.m. PT / 12:00 p.m. ET.

A live webcast with accompanying slide presentation, and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar(®) Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has also launched a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.

React to this article
Latest news on QUESTCOR PHARMACEUTICALS I
02/03DJMallinckrodt Earnings Soar on Acquisitions -- 2nd Update
02/03DJMallinckrodt Earnings Soar on Acquisitions -- Update
02/03DJMallinckrodt Earnings Soar on Acquisitions
2014DJMallinckrodt Sales Surge on Acquisitions in Specialty Pharma Segment
2014 QUESTCOR PHARMACEUTICALS : Mallinckrodt Acquires Questcor Pharmaceuticals
2014 QUESTCOR PHARMACEUTICALS : Mallinckrodt Completes Acquisition Of Questcor Pharma..
2014 QUESTCOR PHARMACEUTICALS : Mallinckrodt Purchases Questcor Pharmaceuticals
2014DJJOHN PAULSON : Paulson & Co. Opens Positions in Covidien, DirecTV and Allergan
2014 QUESTCOR PHARMACEUTICALS : Completion of Acquisition or Disposition of Assets, N..
2014 QUESTCOR PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Rhode Island (Au..